Spots Global Cancer Trial Database for A Study of ABBV-011 Alone and in Combination With Budigalimab (ABBV-181) in Participants With Relapsed or Refractory Small Cell Lung Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of ABBV-011 Alone and in Combination With Budigalimab (ABBV-181) in Participants With Relapsed or Refractory Small Cell Lung Cancer
Official Title: A Phase I Study of ABBV-011 as a Single-Agent and in Combination With Budigalimab (ABBV-181) in Subjects With Relapsed or Refractory Small Cell Lung Cancer
Study ID: NCT03639194
Conditions
Study Description
Brief Summary: This is a multicenter, open-label, Phase 1 study of ABBV-011 given as a single agent and in combination with budigalimab (ABBV-181) in participants with relapsed or refractory small cell lung cancer (SCLC). The study consists of 4 parts: Part A is a single-agent ABBV-011 dose regimen finding cohort; followed by Part B, a single-agent ABBV-011 dose expansion cohort; and then Part C, an ABBV-011 and budigalimab (ABBV-181) combination escalation and expansion cohort; Part D, single-agent ABBV-011 dose-evaluating cohort for Japan.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
University of Alabama at Birmingham - Main /ID# 207295, Birmingham, Alabama, United States
Highlands Oncology Group, PA /ID# 207176, Springdale, Arkansas, United States
University of California, Davis Comprehensive Cancer Center /ID# 207548, Sacramento, California, United States
Yale School of Medicine /ID# 207559, New Haven, Connecticut, United States
University of Iowa Hospitals and Clinics /ID# 207560, Iowa City, Iowa, United States
University of Kentucky Chandler Medical Center /ID# 208217, Lexington, Kentucky, United States
Massachusetts General Hospital /ID# 207549, Boston, Massachusetts, United States
Dana-Farber Cancer Institute /ID# 213032, Boston, Massachusetts, United States
University of Michigan Comprehensive Cancer Center /ID# 207177, Ann Arbor, Michigan, United States
Henry Ford Hospital /ID# 233539, Detroit, Michigan, United States
Washington University-School of Medicine /ID# 207168, Saint Louis, Missouri, United States
Memorial Sloan Kettering Cancer Center-Koch Center /ID# 208216, New York, New York, United States
Duke Cancer Center /ID# 207547, Durham, North Carolina, United States
UH Cleveland Medical Center /ID# 207561, Cleveland, Ohio, United States
The Ohio State University /ID# 207552, Columbus, Ohio, United States
Tennessee Oncology, PLLC /ID# 207175, Nashville, Tennessee, United States
Vanderbilt Ingram Cancer Center /ID# 207551, Nashville, Tennessee, United States
NEXT Oncology /ID# 207167, San Antonio, Texas, United States
University of Utah /ID# 207553, Salt Lake City, Utah, United States
University of Washington /ID# 207557, Seattle, Washington, United States
Univ of Wisconsin Hosp/Clinics /ID# 207556, Madison, Wisconsin, United States
National Cancer Center Hospital East /ID# 230943, Kashiwa-shi, Chiba, Japan
National Hospital Organization Shikoku Cancer Center /ID# 229737, Matsuyama-shi, Ehime, Japan
Hokkaido Cancer Center /ID# 229101, Sapporo-shi, Hokkaido, Japan
Shizuoka Cancer Center /ID# 230911, Sunto-gun, Shizuoka, Japan
Wakayama Medical University Hospital /ID# 229111, Wakayama-shi, Wakayama, Japan
National Cancer Center /ID# 240169, Goyang, Gyeonggido, Korea, Republic of
Seoul National University Bundang Hospital /ID# 234274, Seongnam, Gyeonggido, Korea, Republic of
Yonsei University Health System Severance Hospital /ID# 239515, Seoul, Seoul Teugbyeolsi, Korea, Republic of
Seoul National University Hospital /ID# 234272, Seoul, , Korea, Republic of
Asan Medical Center /ID# 234273, Seoul, , Korea, Republic of
National Cheng Kung University Hospital /ID# 234267, Tainan, , Taiwan
Contact Details
Name: ABBVIE INC.
Affiliation: AbbVie
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
